Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc.

ARRY

ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Array BioPharma Inc. (“Array” or the “Company”) (NASDAQ:ARRY) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/ARRY-Info-Request-Form-1738 . There is no cost or obligation to you.

On March 19, 2017, Array BioPharma announced it had withdrawn its New Drug Application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma. Array BioPharma said the company “concluded that the clinical benefit demonstrated in the Phase 3 NEMO clinical trial would not be found sufficient to support approval of the NRAS-mutant melanoma NDA.”

Then on March 21, 2017, an article featured on Endpoints News suggested that this move comes as a surprise, as the Company had issued positive statements about the drug treatment, noting “execs are walking back the application” just fifteen months after suggesting it had the data needed for its first approval of binimetinib for NRAS-positive melanoma.” Endpoints News also noted that “in late 2015…CEO Ron Squarer said that their MEK blocker hit the primary endpoint on progression-free survival, with the drug registering 2.8 months compared to 1.5 months for a group on dacarbazine. It didn’t look like much, but Array said it was plenty to take to the FDA.” Shares of Array BioPharma have fallen from a close of $10.56 on March 17, 2017 to a close of $8.35 per share on July 14, 2017.

To learn more about the investigation of Array contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ARRY-Info-Request-Form-1738 .

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax: 866.699.3880
vw@wongesq.com